Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of Therapeutic Monitoring of CellCept (Mycophenolate Mofetil) After Kidney Transplantation

This study has been completed.
Information provided by (Responsible Party):
Hoffmann-La Roche Identifier:
First received: July 12, 2004
Last updated: November 3, 2014
Last verified: November 2014

This 3 arm study will evaluate the efficacy and safety of various dosing regimen s of CellCept combined with various dosing regimens of cyclosporine or tacrolimu s in kidney transplantation patients. Patients will be randomized to one of 3 do sing regimens to receive concentration-controlled CellCept with reduced cyclospo rine or tacrolimus, concentration-controlled CellCept with standard cyclosporine or tacrolimus, or fixed-dose CellCept (1g bid) with standard cyclosporine or ta crolimus. The anticipated time on study treatment is 1-2 years, and the target s ample size is 500+ individuals.

Condition Intervention Phase
Kidney Transplantation
Drug: Cyclosporine or tacrolimus
Drug: mycophenolate mofetil [CellCept]
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized, Open-label Study of Various Dosing Regimens of CellCept Combined With Various Dosing Regimens of Cyclosporine or Tacrolimus on Treatment Failure in Kidney Transplantation Patients

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Percentage of patients experiencing treatment failure [ Time Frame: Within 12 months post-transplant ] [ Designated as safety issue: No ]
  • Renal allograft function (by GFR) [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • AEs [ Time Frame: Throughout study ] [ Designated as safety issue: No ]

Enrollment: 717
Study Start Date: July 2004
Study Completion Date: January 2008
Primary Completion Date: January 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: Cyclosporine or tacrolimus
Drug: mycophenolate mofetil [CellCept]
Experimental: 2 Drug: Cyclosporine or tacrolimus
Standard, as prescribed
Drug: mycophenolate mofetil [CellCept]
Experimental: 3 Drug: Cyclosporine or tacrolimus
Standard, as prescribed
Drug: mycophenolate mofetil [CellCept]
1g po bid


Ages Eligible for Study:   13 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • male or female patients 13-75 years of age
  • single organ recipient (kidney only) from living (related or unrelated) or cadaveric heart-beating donors
  • patient receiving first or second kidney transplant

Exclusion Criteria:

  • immunosuppressive therapy (except corticosteroid treatment) within previous 28 days for a first transplant and 3 months for a second transplant
  • history of malignancy in last 5 years (except successfully treated localized non-melanoma skin cancer)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00087581

  Show 57 Study Locations
Sponsors and Collaborators
Hoffmann-La Roche
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

No publications provided

Responsible Party: Hoffmann-La Roche Identifier: NCT00087581     History of Changes
Other Study ID Numbers: ML17225
Study First Received: July 12, 2004
Last Updated: November 3, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Mycophenolate mofetil
Mycophenolic Acid
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Antineoplastic Agents
Antirheumatic Agents
Dermatologic Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on November 24, 2014